Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,816,858
  • Shares Outstanding, K 192,650
  • Annual Sales, $ 3,696 M
  • Annual Income, $ 597,600 K
  • EBIT $ -53 M
  • EBITDA $ 30 M
  • 60-Month Beta 0.71
  • Price/Sales 3.67
  • Price/Cash Flow 28.91
  • Price/Book 4.28

Options Overview Details

View History
  • Implied Volatility 47.37% ( +2.14%)
  • Historical Volatility 48.41%
  • IV Percentile 96%
  • IV Rank 70.90%
  • IV High 59.38% on 11/19/24
  • IV Low 18.10% on 05/16/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 1,848
  • Volume Avg (30-Day) 3,209
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 40,057
  • Open Int (30-Day) 31,543

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.26
  • Number of Estimates 9
  • High Estimate 1.69
  • Low Estimate 0.42
  • Prior Year 0.82
  • Growth Rate Est. (year over year) +53.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.76 +10.75%
on 10/23/24
83.95 -14.57%
on 11/08/24
+6.13 (+9.35%)
since 10/22/24
3-Month
61.15 +17.29%
on 09/05/24
83.95 -14.57%
on 11/08/24
+8.70 (+13.81%)
since 08/22/24
52-Week
50.35 +42.44%
on 04/30/24
83.95 -14.57%
on 11/08/24
+18.32 (+34.31%)
since 11/22/23

Most Recent Stories

More News
What Are Wall Street Analysts' Target Price for Incyte Stock?

Despite Incyte Corporation’s underperformance relative to the broader S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.

XLV : 144.16 (+0.09%)
$SPX : 5,969.34 (+0.35%)
INCY : 71.72 (+1.89%)
Nasdaq Futures Gain With Focus on Nvidia Earnings

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.14% this morning as investors shifted their focus to a highly anticipated earnings report from AI darling Nvidia.

TGT : 125.01 (+2.81%)
NVDA : 141.95 (-3.22%)
TJX : 121.47 (+1.42%)
SNOW : 167.44 (-2.28%)
SMCI : 33.15 (+11.62%)
NQZ24 : 20,849.75s (+0.10%)
SGMO : 1.8800 (-4.08%)
POWL : 289.88 (+0.66%)
SGE.LN : 1,277.625 (+0.96%)
KEYS : 170.28 (-0.09%)
CHWY : 34.89 (-2.73%)
INCY : 71.72 (+1.89%)
Stocks Settle Mostly Higher on Strength in Nvidia and Big Tech

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.28%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.71%. Stocks on Tuesday...

GOOGL : 164.76 (-1.71%)
UAL : 95.24 (+0.89%)
INTU : 640.12 (-5.68%)
KHC : 31.81 (+2.32%)
$IUXX : 20,776.23 (+0.17%)
STM : 24.48 (-0.24%)
BNTX : 113.13 (+4.53%)
ZNZ24 : 109-205s (+0.13%)
TSLA : 352.56 (+3.80%)
$DOWI : 44,296.51 (+0.97%)
MDT : 86.21 (+1.73%)
SPY : 595.51 (+0.31%)
Incyte Sinks On Setback For 2 Drugs Acquired In $750M Buyout: Retail Chatter Hits One-Year High

Incyte suspended testing of a drug candidate acquired through its April acquisition of Escient Pharmaceuticals and abandoned development of another, undermining its diversification strategy.

VOO : 547.47 (+0.34%)
INCY : 71.72 (+1.89%)
VTI : 296.51 (+0.49%)
SPY : 595.51 (+0.31%)
Stocks Recover from Early Losses on Strength in Nvidia and Walmart

The S&P 500 Index ($SPX ) (SPY ) today is down -0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.11%. Stocks are mixed today, with...

INTU : 640.12 (-5.68%)
KHC : 31.81 (+2.32%)
$IUXX : 20,776.23 (+0.17%)
STM : 24.48 (-0.24%)
BNTX : 113.13 (+4.53%)
ZNZ24 : 109-205s (+0.13%)
RTX : 120.77 (+0.20%)
$DOWI : 44,296.51 (+0.97%)
MDT : 86.21 (+1.73%)
SPY : 595.51 (+0.31%)
DIA : 443.16 (+0.95%)
LHX : 248.16 (+0.63%)
Stocks Fall on Escalation of Ukraine-Russian War

The S&P 500 Index ($SPX ) (SPY ) today is down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.40%. Stocks are retreating today,...

CRWD : 372.26 (+4.11%)
NOC : 496.87 (+0.09%)
$SPX : 5,969.34 (+0.35%)
SMCI : 33.15 (+11.62%)
SYM : 38.78 (+6.93%)
ACM : 116.31 (+3.33%)
$IUXX : 20,776.23 (+0.17%)
STM : 24.48 (-0.24%)
BKKT : 29.31 (-5.76%)
BNTX : 113.13 (+4.53%)
QQQ : 505.79 (+0.16%)
ZNZ24 : 109-205s (+0.13%)
Stock Index Futures Slip on Worries Over Russia-Ukraine Escalation, U.S. Housing Data and Walmart Earnings on Tap

December S&P 500 E-Mini futures (ESZ24) are down -0.40%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.32% this morning as risk sentiment took a hit after Russian President Vladimir Putin...

NVDA : 141.95 (-3.22%)
QS : 5.16 (+2.38%)
SMCI : 33.15 (+11.62%)
SYM : 38.78 (+6.93%)
NQZ24 : 20,849.75s (+0.10%)
TKA.D.DX : 3.783 (-2.42%)
TSLA : 352.56 (+3.80%)
LOW : 264.68 (-0.20%)
CHPT : 1.1500 (+1.77%)
KEYS : 170.28 (-0.09%)
AMD : 138.35 (+0.63%)
INCY : 71.72 (+1.89%)
Incyte: Q3 Earnings Snapshot

Incyte: Q3 Earnings Snapshot

INCY : 71.72 (+1.89%)
What to Expect From Incyte's Next Quarterly Earnings Report

Incyte will release its third-quarter earnings later this month, and analysts anticipate a double-digit profit growth.

XLV : 144.16 (+0.09%)
$SPX : 5,969.34 (+0.35%)
INCY : 71.72 (+1.89%)
Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

GUD.TO : 5.29 (-0.19%)
INCY : 71.72 (+1.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 74.04
2nd Resistance Point 73.02
1st Resistance Point 72.37
Last Price 71.72
1st Support Level 70.70
2nd Support Level 69.68
3rd Support Level 69.03

See More

52-Week High 83.95
Last Price 71.72
Fibonacci 61.8% 71.11
Fibonacci 50% 67.15
Fibonacci 38.2% 63.19
52-Week Low 50.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar